Tuberculosis: The Silent Global Threat & Why Progress Is Too Slow

Millions of people around the world carry the bacteria that causes tuberculosis without ever developing the disease, a reality that underscores the complex and often silent nature of this global health challenge. While many view tuberculosis as a disease of the past, it remains a leading cause of infection-related death worldwide. March 24th marks World Tuberculosis Day, a date that often goes unnoticed despite the ongoing impact of this illness.

A Silent Reservoir: The Prevalence of Latent TB

It’s estimated that approximately one in four people globally harbor Mycobacterium tuberculosis, the bacteria responsible for TB, in their bodies. In the vast majority of cases, this bacterium remains dormant – a state known as latent tuberculosis infection. Individuals with latent TB don’t experience symptoms, aren’t easily detected through standard testing, and cannot transmit the disease. However, this seemingly benign coexistence is deceptive. When the immune system weakens, for example due to HIV infection, malnutrition, or certain medications, the bacteria can reactivate, leading to active TB disease, which typically affects the lungs but can also impact other organs. Mayo Clinic provides further information on TB symptoms and causes.

Global Disparities in TB Incidence and Mortality

In 2021, around 9.4 million new cases of tuberculosis were reported globally, resulting in 1.35 million deaths. These figures, published in The Lancet, highlight the continued burden of the disease. However, the distribution of TB is far from uniform. While incidence and mortality rates have steadily declined in high-income countries, where early diagnosis and effective treatment are more readily available, the disease remains a daily reality in many regions of Africa, Asia, and Latin America. Factors such as overcrowding, poverty, malnutrition, and limited access to healthcare contribute to both transmission and disease progression. This disparity underscores the fact that tuberculosis isn’t solely a medical issue; it’s a social and economic one as well.

Progress and Persistent Challenges: The “End TB” Strategy

Significant progress has been made in the fight against tuberculosis since the 1990s, with global incidence and mortality rates decreasing. The expansion of control programs, increased access to effective treatments, and strengthened surveillance systems have all played a role. The World Health Organization (WHO) launched the “End TB” strategy, setting ambitious targets for 2020, including a 20% reduction in incidence and a 35% reduction in mortality compared to 2015 levels. Unfortunately, these goals were not met. Between 2015 and 2020, global TB incidence decreased by only 6.3%, and mortality by 11.9%. The Lancet report details these setbacks, indicating that the pace of improvement is insufficient to reach the 2035 targets.

Uneven Progress and Vulnerable Populations

The progress made against TB has not been consistent across all countries, and populations. Some nations have achieved notable advances through innovative strategies like active case finding – proactively searching for individuals with TB – and the implementation of faster diagnostic technologies. Support programs designed to ensure patients complete their treatment regimens have also proven effective. However, these successes remain the exception rather than the rule. Data also reveals disparities within populations; advancements have been more rapid in children, while progress has been slower among older adults, who are at higher risk of TB-related mortality. This is particularly concerning given the global trend of an aging population, and highlights the need for targeted interventions to protect this vulnerable group.

Beyond the Bacteria: Addressing Underlying Risk Factors

Tuberculosis isn’t solely determined by exposure to the bacteria. Several factors can increase an individual’s risk of developing active disease. Smoking, alcohol consumption, and diabetes are all significant contributors. Recent estimates suggest that a substantial proportion of TB deaths could be prevented by addressing these modifiable risk factors. Research published in Science explores the link between lifestyle factors and TB risk. This reinforces the idea that a comprehensive approach, combining medical interventions with broader public health and social initiatives, is essential to effectively combat the disease.

The Growing Threat of Drug-Resistant TB

A particularly concerning development is the rise of tuberculosis resistant to antibiotics. Standard TB treatment is lengthy and complex, requiring strict adherence to medication regimens. When treatment is incomplete or access to medications is inconsistent, drug-resistant strains can emerge. These forms of TB are significantly more difficult to treat, requiring longer, more expensive therapies with more adverse side effects. Drug-resistant TB is now present in multiple regions worldwide, posing a serious threat to global health security. The National Institutes of Health provides information on drug-resistant tuberculosis.

Implementing Knowledge Equitably: The Path Forward

The challenge isn’t a lack of knowledge about tuberculosis – we know how to prevent it, diagnose it, and treat it. The critical gap lies in the equitable implementation of this knowledge. Reducing the impact of TB in Latin America, and particularly among vulnerable populations, requires a coordinated, equitable, and ambitious global response. Diseases that seem distant can quickly resurface when we least expect them. Effective control requires sustained investment in healthcare infrastructure, robust surveillance systems, and a commitment to addressing the social determinants of health that fuel the spread of this preventable disease.

Luis Felipe Reyes, Professor of very high prestige in Infectious Diseases, Universidad de La Sabana

This article was originally published in The Conversation. Read the original.